Sleep Apnea

A sleep study bed set up for an overnight test
A sleep study bed set up for an overnight test
😴 Interactive Visualization Sleep Apnea — collapse the airway, then splint it open with CPAP Watch the throat close as sleep deepens, the chest heave against a shut airway and oxygen slide into the 80s — then switch on CPAP and see the whole night go quiet. Launch →

Table of Contents

  1. Types of Sleep Apnea
  2. Epidemiology and Risk Factors
  3. Symptoms
  4. Health Consequences
  5. Diagnosis
  6. CPAP Therapy
  7. Alternatives to CPAP
  8. Weight Loss and Lifestyle
  9. Key Research Papers
  10. Connections
  11. Featured Videos

Types of Sleep Apnea

Sleep apnea is a disorder characterized by repeated episodes of stopped or severely reduced breathing during sleep. There are three distinct types:

An "apnea" is a complete pause in breathing lasting at least 10 seconds. A "hypopnea" is a partial reduction in airflow of ≥30% with an oxygen desaturation or arousal. The Apnea-Hypopnea Index (AHI) counts these events per hour of sleep and is the primary diagnostic measure.

Epidemiology and Risk Factors

Sleep apnea is far more common than most people realize — and vastly underdiagnosed:

Key risk factors:

Symptoms

Sleep apnea symptoms span both nighttime (reported by bed partners) and daytime (experienced by the patient):

Health Consequences

Untreated sleep apnea is not merely a quality-of-life issue — it is a serious medical condition with life-threatening cardiovascular consequences:

Diagnosis

Diagnosing sleep apnea requires an objective sleep study, not just a clinical history:

CPAP Therapy

Continuous Positive Airway Pressure (CPAP) is the gold standard treatment for OSA. It delivers a continuous stream of pressurized air through a mask that physically holds the upper airway open, preventing collapse. When used properly, CPAP eliminates virtually all apneas and hypopneas (AHI reduction >90%).

Benefits of CPAP adherence:

The largest trial of CPAP and heart outcomes, SAVE (published in 2016), randomly assigned 2,717 adults aged 45 to 75 with moderate-to-severe OSA and existing heart or brain-vessel disease to CPAP plus usual care or usual care alone. People in the CPAP group used it for an average of 3.3 hours a night. After an average of 3.7 years, heart attacks, strokes and the other cardiovascular events counted in the trial occurred in 17.0% of the CPAP group and 15.4% of the usual-care group — CPAP did not prevent them. CPAP did reduce snoring and daytime sleepiness and improved mood and quality of life.

The major challenge with CPAP is adherence. Studies show only 40–60% of patients use CPAP consistently (>4 hours per night on >70% of nights). Approaches used to support adherence:

Alternatives to CPAP

For patients who cannot tolerate or refuse CPAP, several alternatives exist:

Weight Loss and Lifestyle

Weight loss is the most effective long-term treatment for OSA in obese patients, but it is rarely sufficient as the sole intervention for moderate-severe disease:

Key Research Papers

Key peer-reviewed studies on sleep apnea epidemiology, consequences, and treatment. Each PMID link opens the study on PubMed.

  1. Young T, Peppard PE, Gottlieb DJ. Epidemiology of obstructive sleep apnea: a population health perspective. Am J Respir Crit Care Med. 2002;165(9):1217-1239. — PubMed PMID: 11991871
  2. Peppard PE, Young T, Barnet JH, et al. Increased prevalence of sleep-disordered breathing in adults. Am J Epidemiol. 2013;177(9):1006-1014. — PubMed PMID: 23589584
  3. Marin JM, Carrizo SJ, Vicente E, Agusti AG. Long-term cardiovascular outcomes in men with obstructive sleep apnoea-hypopnoea with or without treatment with continuous positive airway pressure: an observational study. Lancet. 2005;365(9464):1046-1053. — PubMed PMID: 15781100
  4. Punjabi NM, Caffo BS, Goodwin JL, et al. Sleep-disordered breathing and mortality: a prospective cohort study. PLoS Med. 2009;6(8):e1000132. — PubMed PMID: 19688045
  5. Shamsuzzaman AS, Gersh BJ, Somers VK. Obstructive sleep apnea: implications for cardiac and vascular disease. JAMA. 2003;290(14):1906-1914. — PubMed PMID: 14532320
  6. Strollo PJ Jr, Soose RJ, Maurer JT, de Vries N, Cornelius J, Froymovich O, et al.; STAR Trial Group. Upper-airway stimulation for obstructive sleep apnea. N Engl J Med. 2014;370(2):139-149. — PubMed PMID: 24401051
  7. Collop NA, et al. Clinical guidelines for the use of unattended portable monitors in the diagnosis of obstructive sleep apnea in adult patients. Portable Monitoring Task Force of the American Academy of Sleep Medicine. J Clin Sleep Med. 2007;3(7):737-747. — PubMed PMID: 18198809
  8. Kushida CA, et al. Practice parameters for the treatment of snoring and obstructive sleep apnea with oral appliances: an update for 2005. Sleep. 2006;29(2):240-243. — PubMed PMID: 16494092
  9. Gottlieb DJ, Punjabi NM. Diagnosis and management of obstructive sleep apnea: a review. JAMA. 2020;323(14):1389-1400. — PubMed PMID: 32286648
  10. Peppard PE, Young T, Palta M, et al. Longitudinal study of moderate weight change and sleep-disordered breathing. JAMA. 2000;284(23):3015-3021. — PubMed PMID: 11122588
  11. Tregear S, Reston J, Schoelles K, Phillips B. Obstructive sleep apnea and risk of motor vehicle crash: systematic review and meta-analysis. J Clin Sleep Med. 2009;5(6):573-581. — PubMed PMID: 20465027
  12. Tregear S, Reston J, Schoelles K, Phillips B. Continuous positive airway pressure reduces risk of motor vehicle crash among drivers with obstructive sleep apnea: systematic review and meta-analysis. Sleep. 2010;33(10):1373-1380. — PubMed PMID: 21061860
  13. McEvoy RD, Antic NA, Heeley E, Luo Y, Ou Q, Zhang X, et al.; SAVE Investigators and Coordinators. CPAP for prevention of cardiovascular events in obstructive sleep apnea. N Engl J Med. 2016;375(10):919-931. — PubMed PMID: 27571048
  14. Woodson BT, Strohl KP, Soose RJ, Gillespie MB, Maurer JT, de Vries N, et al. Upper airway stimulation for obstructive sleep apnea: 5-year outcomes. Otolaryngol Head Neck Surg. 2018;159(1):194-202. — PubMed PMID: 29582703
  15. Malhotra A, Grunstein RR, Fietze I, Weaver TE, Redline S, Azarbarzin A, et al.; SURMOUNT-OSA Investigators. Tirzepatide for the treatment of obstructive sleep apnea and obesity. N Engl J Med. 2024;391(13):1193-1205. — PubMed PMID: 38912654
  16. Hassan MG, Hassan DG, Hassan GA. Tirzepatide gains US Food and Drug Administration approval for the management of obstructive sleep apnea: implications for oral health care providers. J Am Dent Assoc. 2025;156(8):620-625. — PubMed PMID: 40569229

Curated PubMed topic searches:

  1. PubMed: CPAP treatment
  2. PubMed: Cardiovascular risk
  3. PubMed: Polysomnography diagnosis
  4. PubMed: Weight loss and OSA
  5. PubMed: Hypoglossal nerve stimulation
  6. PubMed: OSA and atrial fibrillation
  7. PubMed: Oral appliance therapy
  8. PubMed: Cognitive decline and OSA

Back to Table of Contents

Connections

Back to Table of Contents